- Email: [email protected]
Prognostic Impact of Survivin Expression in Cervical Squamous Cell Carcinomas Treated With Radiation Therapy
Proceedings of the 47th Annual ASTRO Meeting
number of segments and MU allow better dose calculation and delivery precision, shorter treatment time and less scatter radiation. Clinical results of treatment tolerance will follow. References: 1F. Beaulieu et al. Simultaneous optimization of beam orientations, wedge filters and field weights for inverse planning with anatomy-based MLC fields. Med.Phys.31, 1546 –1557(2004).
2195
Prognostic Impact of Survivin Expression in Cervical Squamous Cell Carcinomas Treated With Radiation Therapy
Y. Suzuki,1 K. Oka,3 D. Yoshida,1 T. Ohno,2 S. Kato,2 H. Tsujii,2 T. Nakano1 Radiation Oncology, Gunma University, Maebashi, Japan, 2Research Center Hospital of Charged Particle Therapy National Institute of Radiological Sciences,, Chiba, Japan, 3Pathology, Mito Saiseikai General Hospital, Mito, Japan 1
Purpose/Objective: Survivin is a member of the inhibitor of apoptosis family that has been implicated in both regulating cell division and in suppressing apoptosis. Survivin is expressed in most of human malignant tumors. Overexpression of cytoplasmic survivin correlate with unfavorable prognosis in many malignant tumors. However, prognostic value of the nuclear survivin expression is still equivocal. This study is the first report investigating the prognostic value of survivin expression in cervical cancer treated with radiation therapy. Materials/Methods: Tissue sections were obtained from 72 patients with cervical squamous cell carcinoma treated with radiation therapy alone. Survivin expression levels were determined by immunohistochemical staining, and evaluated for cell positivity. The correlation between survivin expression and clinical outcome endpoints including disease-free survival and local control were evaluated. Results: A total of 14% of the tissue specimens demonstrated more than 5% nucleus positivity, and a total of 47% of the tissue specimens demonstrated more than 50% cytoplasmic positivity. The local control rate of the cytoplasmic survivin negative tumors was 94%, significantly higher than the 76% of positive tumors (p⫽0.046). The local control rate of nucleus survivin positive and cytoplasmic surviving negative patients was 74%, significantly lower than 95% in other patients (p⫽0.02), whereas no significant correlation was noted between surviving expressions and disease-free survival. Conclusions: Combination of nucleus and cytoplasmic, and cytoplasmic survivin expression appears to be good predictor for local control in patients with cervical squamous cell carcinoma treated with radiation therapy alone. Distribution of the 72 patients according to combined nuclear and cytoplasm survivin expressions.
2196
Revisiting Stage III Endometrial Cancer Subcategories
R.K. Oldroyd, A. Guirguis, H. Ashamalla, H. Selim, K. Parikh, S. Rafla Radiation Oncology, New York Methodist Hospital, Brooklyn, NY Purpose/Objective: Stage III endometrial cancer represents 13% of all uterine cancer cases. There is debate about the significance of stage III subcategories, namely: A) serosal involvement, B) positive peritoneal washing, C) vaginal involvement,
S345
number of segments and MU allow better dose calculation and delivery precision, shorter treatment time and less scatter radiation. Clinical results of treatment tolerance will follow. References: 1F. Beaulieu et al. Simultaneous optimization of beam orientations, wedge filters and field weights for inverse planning with anatomy-based MLC fields. Med.Phys.31, 1546 –1557(2004).
2195
Prognostic Impact of Survivin Expression in Cervical Squamous Cell Carcinomas Treated With Radiation Therapy
Y. Suzuki,1 K. Oka,3 D. Yoshida,1 T. Ohno,2 S. Kato,2 H. Tsujii,2 T. Nakano1 Radiation Oncology, Gunma University, Maebashi, Japan, 2Research Center Hospital of Charged Particle Therapy National Institute of Radiological Sciences,, Chiba, Japan, 3Pathology, Mito Saiseikai General Hospital, Mito, Japan 1
Purpose/Objective: Survivin is a member of the inhibitor of apoptosis family that has been implicated in both regulating cell division and in suppressing apoptosis. Survivin is expressed in most of human malignant tumors. Overexpression of cytoplasmic survivin correlate with unfavorable prognosis in many malignant tumors. However, prognostic value of the nuclear survivin expression is still equivocal. This study is the first report investigating the prognostic value of survivin expression in cervical cancer treated with radiation therapy. Materials/Methods: Tissue sections were obtained from 72 patients with cervical squamous cell carcinoma treated with radiation therapy alone. Survivin expression levels were determined by immunohistochemical staining, and evaluated for cell positivity. The correlation between survivin expression and clinical outcome endpoints including disease-free survival and local control were evaluated. Results: A total of 14% of the tissue specimens demonstrated more than 5% nucleus positivity, and a total of 47% of the tissue specimens demonstrated more than 50% cytoplasmic positivity. The local control rate of the cytoplasmic survivin negative tumors was 94%, significantly higher than the 76% of positive tumors (p⫽0.046). The local control rate of nucleus survivin positive and cytoplasmic surviving negative patients was 74%, significantly lower than 95% in other patients (p⫽0.02), whereas no significant correlation was noted between surviving expressions and disease-free survival. Conclusions: Combination of nucleus and cytoplasmic, and cytoplasmic survivin expression appears to be good predictor for local control in patients with cervical squamous cell carcinoma treated with radiation therapy alone. Distribution of the 72 patients according to combined nuclear and cytoplasm survivin expressions.
2196
Revisiting Stage III Endometrial Cancer Subcategories
R.K. Oldroyd, A. Guirguis, H. Ashamalla, H. Selim, K. Parikh, S. Rafla Radiation Oncology, New York Methodist Hospital, Brooklyn, NY Purpose/Objective: Stage III endometrial cancer represents 13% of all uterine cancer cases. There is debate about the significance of stage III subcategories, namely: A) serosal involvement, B) positive peritoneal washing, C) vaginal involvement,
S345